U.S. Aptamers Market Size, Share & Trends Analysis Report By Type (Nucleic Acid Aptamer, Peptide Aptamer), By Application (Diagnostics, Therapeutics, Research & Development, Others), And Segment Forecasts, 2024 - 2030
- Report ID: GVR-4-68040-242-3
- Number of Pages: 80
- Format: Electronic (PDF)
- Historical Range: 2018 - 2023
- Industry: Healthcare
Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.2. Information Or Data Analysis
1.3. Market Scope & Segment Definition
1.4. Market Model
1.4.1. Market Study, By Company Market Share
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. High Advantage of Aptamers Compared to Antibodies
3.2.1.2. Advancements In the Field of Aptamer Development Technologies
3.2.1.3. Growing Interest of Many Companies to Invest In Aptamers Market
3.2.1.4. Promising Pipeline of Therapeutics
3.2.2. Market Restraint Analysis
3.2.2.1. Rising Number of Setbacks of Aptamer Therapeutics in Late Stage Clinical Studies
3.2.2.2. Low Awareness Level and Incomplete Regulatory Policies Slow Down the Market Growth
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. U.S. Aptamers Market: Segment Dashboard
4.2. U.S. Aptamers Market: Type Movement Analysis
4.3. Nucleic Acid Aptamer
4.3.1. Nucleic Acid Aptamer Market, 2018 - 2030 (USD Million)
4.4. Peptide Aptamer
4.4.1. Peptide Aptamer Market, 2018 - 2030 (USD Million)
Chapter 5. Application Business Analysis
5.1. U.S. Aptamers Market: Segment Dashboard
5.2. U.S. Aptamers Market: Application Movement Analysis
5.3. Diagnostics
5.3.1. Diagnostics Market, 2018 - 2030 (USD Million)
5.4. Therapeutics
5.4.1. Therapeutics Market, 2018 - 2030 (USD Million)
5.5. Research and Development
5.5.1. Research and Development Market, 2018 - 2030 (USD Million)
5.6. Others
5.6.1. Other Applications Market, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Company Categorization
6.2. Strategy Mapping
6.3. Company Market Position Analysis, 2023
6.4. Company Profiles/Listing
6.4.1. SomaLogic
6.4.1.1. Overview
6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.1.3. Product Benchmarking
6.4.1.4. Strategic Initiatives
6.4.2. Aptamer Group
6.4.2.1. Overview
6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.2.3. Product Benchmarking
6.4.2.4. Strategic Initiatives
6.4.3. Aptadel Therapeutics
6.4.3.1. Overview
6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.3.3. Product Benchmarking
6.4.3.4. Strategic Initiatives
6.4.4. Base Pair Biotechnologies
6.4.4.1. Overview
6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.4.3. Product Benchmarking
6.4.4.4. Strategic Initiatives
6.4.5. Noxxon Pharma
6.4.5.1. Overview
6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.5.3. Product Benchmarking
6.4.5.4. Strategic Initiatives
6.4.6. Aptagen, LLC
6.4.6.1. Overview
6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.6.3. Product Benchmarking
6.4.6.4. Strategic Initiatives
6.4.7. Vivonics Inc.
6.4.7.1. Overview
6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.7.3. Product Benchmarking
6.4.7.4. Strategic Initiatives
6.4.8. TriLink Biotechnologies
6.4.8.1. Overview
6.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.8.3. Product Benchmarking
6.4.8.4. Strategic Initiatives
6.4.9. Altermune LLC
6.4.9.1. Overview
6.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.9.3. Product Benchmarking
6.4.9.4. Strategic Initiatives
6.4.10. AM Biotechnologies
6.4.10.1. Overview
6.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.10.3. Product Benchmarking
6.4.10.4. Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 U.S. aptamers market, by type, 2018 - 2030 (USD Million)
Table 3 U.S. aptamers market, by application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Aptamers market segmentation
Fig. 8 Market snapshot, 2023
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (current & future impact)
Fig. 11 Market restraint relevance analysis (current & future impact)
Fig. 12 PESTEL analysis
Fig. 13 Porter’s Five Forces analysis
Fig. 14 U.S. aptamers market: Type movement analysis
Fig. 15 U.S. aptamers market, for nucleic acid aptamer, 2018 - 2030 (USD Million)
Fig. 16 U.S. aptamers market, for peptide aptamer, 2018 - 2030 (USD Million)
Fig. 17 U.S. aptamers market: application movement analysis
Fig. 18 U.S. aptamers market, for diagnostics, 2018 - 2030 (USD Million)
Fig. 19 U.S. aptamers market, for therapeutics, 2018 - 2030 (USD Million)
Fig. 20 U.S. aptamers market, for research and development, 2018 - 2030 (USD Million)
Fig. 21 U.S. aptamers market, for other applications, 2018 - 2030 (USD Million)
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
